292 related articles for article (PubMed ID: 35062321)
21. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.
Roex MCJ; van Balen P; Germeroth L; Hageman L; van Egmond E; Veld SAJ; Hoogstraten C; van Liempt E; Zwaginga JJ; de Wreede LC; Meij P; Vossen ACTM; Danhof S; Einsele H; Schaafsma MR; Veelken H; Halkes CJM; Jedema I; Falkenburg JHF
Leukemia; 2020 Mar; 34(3):831-844. PubMed ID: 31624377
[TBL] [Abstract][Full Text] [Related]
22. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].
Song T; Chen G; Zhang X; Xu Y; Chen J; Wang Y; Ye L; Xu J; Wu D; Miao J
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3135-9. PubMed ID: 25573307
[TBL] [Abstract][Full Text] [Related]
23. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
24. The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
Ke P; Zhang X; Liu S; Zhu Q; Ma X; Chen F; Tang X; Han Y; Fu Z; Chen S; Wu D; Qiu H; Zhou J; Bao X
Ann Hematol; 2021 Jul; 100(7):1879-1889. PubMed ID: 33885923
[TBL] [Abstract][Full Text] [Related]
25. Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis.
Arruda LCM; Gaballa A; Uhlin M
Blood Adv; 2019 Nov; 3(21):3436-3448. PubMed ID: 31714966
[TBL] [Abstract][Full Text] [Related]
26. The Value of Torque Teno Virus (TTV) as a Marker for the Degree of Immunosuppression in Adult Patients after Hematopoietic Stem Cell Transplantation (HSCT).
Schmitz J; Kobbe G; Kondakci M; Schuler E; Magorsch M; Adams O
Biol Blood Marrow Transplant; 2020 Apr; 26(4):643-650. PubMed ID: 31712192
[TBL] [Abstract][Full Text] [Related]
27. HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns.
Quintela A; Escuret V; Roux S; Bonnafous P; Gilis L; Barraco F; Labussière-Wallet H; Duscastelle-Leprêtre S; Nicolini FE; Thomas X; Chidiac C; Ferry T; Frobert E; Morisset S; Poitevin-Later F; Monneret G; Michallet M; Ader F;
J Infect; 2016 Feb; 72(2):214-22. PubMed ID: 26518057
[TBL] [Abstract][Full Text] [Related]
28. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of Torque Teno virus viremia could predict risk of complications after allogeneic hematopoietic stem cell transplantation.
Gilles R; Herling M; Holtick U; Heger E; Awerkiew S; Fish I; Höller K; Sierra S; Knops E; Kaiser R; Scheid C; Di Cristanziano V
Med Microbiol Immunol; 2017 Oct; 206(5):355-362. PubMed ID: 28702856
[TBL] [Abstract][Full Text] [Related]
30. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
Leen AM; Bollard CM; Mendizabal AM; Shpall EJ; Szabolcs P; Antin JH; Kapoor N; Pai SY; Rowley SD; Kebriaei P; Dey BR; Grilley BJ; Gee AP; Brenner MK; Rooney CM; Heslop HE
Blood; 2013 Jun; 121(26):5113-23. PubMed ID: 23610374
[TBL] [Abstract][Full Text] [Related]
31. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
32. αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies.
de Witte MA; Janssen A; Nijssen K; Karaiskaki F; Swanenberg L; van Rhenen A; Admiraal R; van der Wagen L; Minnema MC; Petersen E; Raymakers RAP; Westinga K; Straetemans T; Halkes CJM; Boelens JJ; Kuball J
Blood Adv; 2021 Jan; 5(1):240-249. PubMed ID: 33570642
[TBL] [Abstract][Full Text] [Related]
33. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
34. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
35. Antigen-specific γδ T cells contribute to cytomegalovirus control after stem cell transplantation.
Prinz I; Koenecke C
Curr Opin Immunol; 2023 Jun; 82():102303. PubMed ID: 36947903
[TBL] [Abstract][Full Text] [Related]
36. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
Norell H; Moretta A; Silva-Santos B; Moretta L
J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
[TBL] [Abstract][Full Text] [Related]
37. Dendritic Cells Are Critical for the Activation and Expansion of Vδ2
Wang X; Liu J; Gao H; Mo XD; Han T; Xu LP; Zhang XH; Huang XJ
Front Immunol; 2018; 9():2528. PubMed ID: 30443256
[TBL] [Abstract][Full Text] [Related]
38. Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay.
Inazawa N; Hori T; Nojima M; Saito M; Igarashi K; Yamamoto M; Shimizu N; Yoto Y; Tsutsumi H
J Med Virol; 2017 Feb; 89(2):358-362. PubMed ID: 27364410
[TBL] [Abstract][Full Text] [Related]
39. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study.
Liu X; Wu M; Peng Y; Chen X; Sun J; Huang F; Fan Z; Zhou H; Wu X; Yu G; Zhang X; Li Y; Xiao Y; Song C; Xiang AP; Liu Q
Cell Transplant; 2014; 23(9):1087-98. PubMed ID: 23294601
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
